A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Dose Escalation, Multiple-Dose Escalation, and Food Effect Study of FLX475 in Healthy Male and Female Subjects
Latest Information Update: 29 May 2019
At a glance
- Drugs Tivumecirnon (Primary)
- Indications Cancer
- Focus Adverse reactions; First in man
- Sponsors RAPT Therapeutics
- 24 May 2019 Status changed from recruiting to completed, according to a FLX Bio media release.
- 24 May 2019 According to an FLX Bio media release, the company has changed its name to RAPT Therapeutics.
- 08 Nov 2018 Results presented in the FLX Bio media release.